Protein vaccine NVX-CoV2373 elicits functional T cell immunity

Protein vaccine NVX-CoV2373 elicits functional T cell immunity

The SARS-CoV-2 vaccine NVX-CoV2373 is a protein-based vaccine that might circumvent the difficulties in distributing mRNA vaccines to regions with limited access to cold-chain and refrigeration. However, the NVX-CoV2373–induced T cell and antibody responses remain poorly understood. In this issue of...

Full description

Bibliographic Details
Main Author:	Pengcheng Zhou
Format:	Article
Language:	English
Published:	American Society for Clinical Investigation 2022-10-01
Series:	The Journal of Clinical Investigation
Online Access:	https://doi.org/10.1172/JCI163614

Similar Items

Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine
by: Eddie Underwood, et al.
Published: (2023-12-01)

Safety and efficacy of NVX-CoV2373 Covid-19 vaccine
by: Heath, PT, et al.
Published: (2021)

Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants
by: Kirsten E. Lyke, et al.
Published: (2023-07-01)

NVX-CoV2373 induces humoral and cellular immune responses that are functionally comparable to vector and mRNA-based vaccines
by: Franz Mai, et al.
Published: (2024-03-01)

Angioedema‐like eyelid edema following the second NVX‐CoV2373 COVID‐19 vaccination
by: Mari Matsumoto, et al.
Published: (2023-10-01)

NVX-CoV2373 vaccination induces functional SARS-CoV-2–specific CD4+ and CD8+ T cell responses
by: Carolyn Rydyznski Moderbacher, et al.
Published: (2022-10-01)

Myopericarditis following both BNT162b2 and NVX-CoV2373
by: Saima Ahmad, et al.
Published: (2022-12-01)

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice
by: Jing-Hui Tian, et al.
Published: (2021-01-01)

Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines
by: Toback, S, et al.
Published: (2021)

Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages
by: Jinal N. Bhiman, et al.
Published: (2023-01-01)

Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination
by: Matthew J. Gorman, et al.
Published: (2021-09-01)

Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination
by: Lauffenburger, Douglas
Published: (2023)

Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines
by: Anthony M. Marchese, et al.
Published: (2023-12-01)

NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines
by: Magdalena Mueller-Enz, et al.
Published: (2023-07-01)

Safety and efficacy of the NVX-CoV2373 coronavirus disease 2019 vaccine at completion of the placebo-controlled phase of a randomized controlled trial
by: Heath, PT, et al.
Published: (2022)

Myopericarditis Associated with the Novavax COVID-19 Vaccine (NVX-CoV2373): A Retrospective Analysis of Individual Case Safety Reports from VigiBase
by: Diego Macías Saint-Gerons, et al.
Published: (2023-02-01)

Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial.
by: Neil Formica, et al.
Published: (2021-10-01)

Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled studyResearch in context
by: Prasad S. Kulkarni, et al.
Published: (2023-03-01)

Cytokine and Chemokine Production in Mice Inoculated with NVX-CoV2373 (Nuvaxovid<sup>®</sup>) in Comparison with Omicron BA.4/5 Bivalent BNT162b2 (Comirnaty<sup>®</sup>)
by: Tetsuo Nakayama, et al.
Published: (2023-11-01)

2373
by: Serena-Kaye Kinley-Cooper, et al.
Published: (2017-09-01)

Comparison of Immune Responses Elicited by SARS-CoV-2 mRNA and Recombinant Protein Vaccine Candidates
by: Yixin Wu, et al.
Published: (2022-05-01)

SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments
by: Gisela Canedo-Marroquín, et al.
Published: (2020-12-01)

SARS-CoV-2: A Glance at the Innate Immune Response Elicited by Infection and Vaccination
by: Nicola Manfrini, et al.
Published: (2024-02-01)

Vaccine-elicited B- and T-cell immunity to SARS-CoV-2 is impaired in chronic lung disease patients
by: Haolin Liu, et al.
Published: (2023-10-01)

Profiling the B cell immune response elicited by vaccination against the respiratory virus SARS-CoV-2
by: Elena Pettini, et al.
Published: (2022-11-01)

Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2
by: Xingyue An, et al.
Published: (2021-09-01)

Potent antibody immunity to SARS‐CoV‐2 variants elicited by a third dose of inactivated vaccine
by: Bin Ju, et al.
Published: (2022-02-01)

Effect of Different Adjuvants on Immune Responses Elicited by Protein-Based Subunit Vaccines against SARS-CoV-2 and Its Delta Variant
by: Naru Zhang, et al.
Published: (2022-02-01)

Durable and enhanced immunity against SARS-CoV-2 elicited by manganese nanoadjuvant formulated subunit vaccine
by: Mengyu Guo, et al.
Published: (2023-12-01)

Self-replicating RNA nanoparticle vaccine elicits protective immune responses against SARS-CoV-2
by: Guibin Lin, et al.
Published: (2023-06-01)

A plant-produced SARS-CoV-2 spike protein elicits heterologous immunity in hamsters
by: Emmanuel Margolin, et al.
Published: (2023-03-01)

DNA vaccine candidate encoding SARS-CoV-2 spike proteins elicited potent humoral and Th1 cell-mediated immune responses in mice.
by: Eakachai Prompetchara, et al.
Published: (2021-01-01)

Correction: Durable and enhanced immunity against SARS-CoV-2 elicited by manganese nanoadjuvant formulated subunit vaccine
by: Mengyu Guo, et al.
Published: (2024-01-01)

SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice
by: Eun Kim, et al.
Published: (2023-06-01)

An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response
by: Li Chen, et al.
Published: (2022-11-01)

Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020)
by: David S. Kim, et al.
Published: (2020-12-01)

SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans
by: David Forgacs, et al.
Published: (2021-09-01)

Treatment of Swine Closed Head Injury with Perfluorocarbon NVX-428
by: Francoise Arnaud, et al.
Published: (2020-09-01)

Distinct BCR repertoires elicited by SARS-CoV-2 RBD and S vaccinations in mice
by: Siyu Tian, et al.
Published: (2021-10-01)

Yeast-produced RBD-based recombinant protein vaccines elicit broadly neutralizing antibodies and durable protective immunity against SARS-CoV-2 infection
by: Jinkai Zang, et al.
Published: (2021-08-01)